Kenvue’s $48.7 Billion Sale and Metsera’s Bidding War Put Healthcare M&A in the Spotlight

November 12, 2025

Healthcare M&A is giving students the cleanest deal discussion right now

If you’re preparing for investment banking recruiting, the most useful stories are the ones that let you connect strategy, valuation, financing, and market reaction in one answer. This week has several, but healthcare M&A is the best place to start.

Kimberly-Clark agreed to buy Kenvue in a cash-and-stock transaction valued at $48.7 billion. The combined company would own 11 brands with more than $1 billion in annual sales, including Kleenex, Cottonelle, Tylenol, and Listerine, with potential annual revenue reaching roughly $32 billion. Kimberly-Clark is paying $21.01 per Kenvue share, while Kenvue traded a little above $16 after the announcement. The initial market reaction was split: Kenvue shares rose 16%, while Kimberly-Clark fell 12%.

That reaction is exactly what you should be ready to discuss in an interview. Sellers often trade up when the offer includes a meaningful premium. Buyers can trade down when investors worry about price paid, integration risk, legal exposure, or whether management is stretching for growth. Here, Kimberly-Clark is trying to strengthen its position in consumer healthcare and add higher-margin products. But Kenvue also brings reputational and legal overhangs, including pressure tied to Tylenol and litigation involving Johnson’s Baby Powder.

The simple banker framing: Kimberly-Clark is buying scale, category expansion, and brand durability, but the market is asking whether those benefits justify the risk and purchase price. That’s a much more complete answer than saying, “It’s a big consumer healthcare deal.”

How to talk about the buyer’s logic

Kimberly-Clark has strong household brands, but it has lagged larger consumer rivals. Kenvue gives it immediate exposure to health-and-wellness categories with major consumer franchises. For a strategic buyer, that matters because cost synergies and distribution leverage can make an acquisition more valuable in its hands than in the public market.

But don’t ignore the negative side. If you were advising the buyer, you’d need to pressure-test whether the brand portfolio is worth the legal and reputational baggage. You’d also want to understand whether Kenvue’s issues are temporary headline risk or something that could pressure future earnings power.

A good interview answer might sound like this:

“I’d frame the Kimberly-Clark-Kenvue deal as a scale and portfolio repositioning transaction. Kimberly-Clark gets deeper exposure to consumer health brands, but the stock reaction suggests investors are concerned about the premium, integration risk, and Kenvue’s legal and reputational issues. The deal creates strategic logic, but the debate is whether Kimberly-Clark is buying a durable platform or taking on too much uncertainty.”

Metsera shows how scarce obesity assets can create auction tension

The other major healthcare story is the bidding war for Metsera, a weight-loss drug developer. Pfizer is competing with Novo Nordisk for the company, with Pfizer’s bid above $10 billion. Bristol Myers Squibb had also explored a takeover before the fight narrowed. The reason is straightforward: analysts expect the weight-loss market to exceed $100 billion by 2030.

Metsera owns a pipeline of at least eight potential drugs in the category. Its lead candidate is a monthly injection that has achieved about 14% greater weight loss than placebo in early trials. That monthly dosing profile is important because current major treatments such as Wegovy and Zepbound are weekly treatments. If a therapy can improve convenience while maintaining strong efficacy, it can become strategically valuable very quickly.

Novo Nordisk, the maker of Ozempic, raised the stakes after Pfizer had already reached an agreement to acquire Metsera. Pfizer then filed a lawsuit challenging Novo’s unsolicited higher offer. This is a classic auction dynamic: the target has scarce assets, the addressable market is enormous, and multiple strategic buyers have strong reasons to win.

For banking interviews, don’t just say “obesity drugs are hot.” Say why the asset matters. Pfizer is trying to regain relevance in a market that could shape the next decade of pharma growth. Novo Nordisk is defending and extending a category where it already has a leading position. Metsera’s pipeline could generate more than $5 billion in potential annual sales, which helps explain why the competitive tension is so intense.

Policy is reshaping healthcare demand, not just pharma valuations

The healthcare theme isn’t limited to M&A. A new agreement with Eli Lilly and Novo Nordisk would expand access to GLP-1 obesity drugs, with Medicare set to cover GLP-1 treatments for the first time beginning in mid-2026. Under the deal, Medicare and Medicaid would pay $245 per month for GLP-1s, while eligible Medicare patients would pay $50 monthly copays for drugs including Zepbound and Wegovy.

That matters because current monthly list prices exceed $1,000 and coverage remains limited across many state Medicaid plans, employers, and private insurers. Eli Lilly’s CEO said the agreement could open access to as many as 40 million new eligible Medicare patients and potentially push commercial insurers to expand coverage.

From a markets perspective, this is a demand unlock. If government coverage expands, utilization can rise. If private insurers follow, the market gets even larger. For students, this is a useful reminder that healthcare valuation depends on more than clinical data. Reimbursement, coverage, patient eligibility, and policy design all feed directly into revenue forecasts.

AI infrastructure is still absorbing huge capital commitments

Outside healthcare, the OpenAI-Amazon Web Services agreement is another strong recruiting talking point. OpenAI and AWS announced a seven-year cloud services deal worth roughly $38 billion. OpenAI will use AWS infrastructure, including hundreds of thousands of Nvidia GPUs and scalable CPU resources, to power models such as ChatGPT.

The strategic read is simple. OpenAI is reducing its dependence on Microsoft and widening its cloud partnerships. AWS, meanwhile, gets a major endorsement in the AI infrastructure race after facing pressure from competitors. Amazon shares rose about 5% after the announcement and reached record highs.

But there’s also a capital intensity question. OpenAI has hinted at a multi-trillion-dollar spending pipeline. That raises the obvious banking-style issue: how much upfront infrastructure spending can be justified by future AI revenue? This is where you can connect corporate strategy with financing needs, cloud capex, vendor concentration, and long-term profitability.

Valuation risk is becoming harder to ignore

Markets are still willing to reward growth, but the valuation backdrop is stretched. The Shiller P/E ratio recently moved above 40 for only the second time in history, a level previously seen around the dot-com peak. Research Affiliates projects large U.S. growth stocks could deliver negative real returns of about 1.1% annually over the next ten years, while small caps and emerging markets have higher expected real return estimates.

This matters in interviews because valuation is not just a technical exercise. It affects deal timing, IPO windows, sponsor activity, and management confidence. When public market multiples are high, strategic buyers may use stock as currency, sellers may push for premium valuations, and investors may become quicker to punish expensive growth stories.

Palantir is a clean example. Shares fell 8% after Michael Burry disclosed a bearish derivatives position against the company. That happened even though Palantir reported strong third-quarter results: revenue rose 63% year over year to $1.18 billion, net income reached $476 million, and 2025 revenue guidance was lifted to $4.4 billion. The issue wasn’t growth. It was valuation. Shares were trading at nearly 230 times forward earnings after climbing more than 170% during the year.

That’s a useful line to remember: great companies can still face pressure if expectations become too aggressive.

Macro remains mixed: tariffs haven’t broken the economy, but risks are delayed

The U.S. economy has remained more resilient than many expected after sweeping tariffs were introduced earlier in the year. Inflation has stayed near 3%, consumer spending has remained steady, and companies have softened the impact by shifting supply chains, using inventory, and absorbing some costs rather than fully passing them to consumers.

The Treasury is on track to collect about $34 billion in October, implying an effective average tariff rate around 12.5%, below the 17% headline estimate. Some firms have moved production from China to lower-tariff countries such as Vietnam and Mexico. Automakers are reportedly absorbing about 80% of tariff costs, with car prices up only 1.1% since March.

Still, the delayed impact matters. Higher trade costs can eventually flow through to prices, hiring, and investment. If you’re asked about tariffs, avoid the lazy answer that tariffs automatically cause an immediate recession. The better answer is that companies have tools to delay the impact, but those tools are not free or unlimited.

What I’d actually prepare for interviews

If you only have time to master a few stories, prioritize the ones that let you sound like a banker rather than a headline reader.

Kimberly-Clark buying Kenvue: Know the premium, the buyer and seller stock reactions, the strategic rationale, and the risk factors.
Pfizer versus Novo Nordisk for Metsera: Understand why scarcity, pipeline value, and market size can create auction tension.
OpenAI’s $38 billion AWS deal: Be ready to discuss AI capex, cloud infrastructure, and supplier diversification.
Palantir’s selloff despite strong results: Use it to explain how valuation risk can overpower near-term fundamentals.
Tariff resilience: Explain why the economy has held up so far, but also why cost pass-through may come later.

The best candidates don’t memorize every market move. They take a few live situations and connect them to valuation, strategic rationale, financing, and investor reaction. That’s the skill this week’s stories are testing.